Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Antihypertensive Therapie bei Diabetes mellitus

Leitlinie der österreichischen Diabetesgesellschaft 2016

verfasst von: Guntram Schernthaner, Heinz Drexel, Alexander Rosenkranz, Gerit-Holger Schernthaner, Bruno Watschinger

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die Blutdrucksenkung ist eine der wichtigsten Maßnahmen, um die vaskulären Komplikationen und die Mortalität bei Patienten mit Diabetes mellitus zu senken. Rezente Studien zeigen, dass die optimalen Blutdruckzielwerte zwischen 130–140 mmHg systolisch und 80–90 mmHg diastolisch liegen dürften. Niedrigere Blutdruckzielwerte (z. B. 120/80 mmHg) können zwar das Risiko für Schlaganfall und diabetische Nephropathie weiter senken, sind aber mit einer erhöhten kardiovaskulären Mortalität assoziiert. Sehr niedrige Blutdruckwerte (< 120 mmHg) sollten insbesondere bei Patienten mit koronarer Herzerkrankung oder mit peripherer arterieller Verschlusskrankheit unbedingt vermieden werden. Der Großteil der Patienten mit Diabetes und Hypertonie benötigt eine antihyper- tensive Kombinationstherapie, wobei ACE-Inhibitoren oder Angiotensin-II-Rezeptorblocker in der First-Line-Therapie eingesetzt werden sollen.
Literatur
1.
Zurück zum Zitat Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601–10. CrossRefPubMed Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601–10. CrossRefPubMed
2.
Zurück zum Zitat Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44. CrossRefPubMed Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44. CrossRefPubMed
3.
Zurück zum Zitat Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–93. CrossRefPubMedPubMedCentral Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–93. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027–37. CrossRefPubMed Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027–37. CrossRefPubMed
5.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2007;28:1462–536. PubMed Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2007;28:1462–536. PubMed
6.
Zurück zum Zitat Wang J, Geiss LS, Cheng YJ, et al. Long-term and recent prog.ress in blood pressure levels among U.S. adults with diagnosed diabetes, 1988–2008. Diabetes Care. 2011;34:1579–81. CrossRefPubMedPubMedCentral Wang J, Geiss LS, Cheng YJ, et al. Long-term and recent prog.ress in blood pressure levels among U.S. adults with diagnosed diabetes, 1988–2008. Diabetes Care. 2011;34:1579–81. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58. CrossRefPubMed Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58. CrossRefPubMed
8.
Zurück zum Zitat Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123:2776–8. CrossRefPubMed Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123:2776–8. CrossRefPubMed
9.
Zurück zum Zitat Garcia-Touza M, Sowers JR. Evidence-based hypertension treatment in patients with diabetes. J Clin Hypertens. 2012;14:97–102. CrossRef Garcia-Touza M, Sowers JR. Evidence-based hypertension treatment in patients with diabetes. J Clin Hypertens. 2012;14:97–102. CrossRef
10.
Zurück zum Zitat Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61. CrossRefPubMed Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61. CrossRefPubMed
11.
Zurück zum Zitat ACCORD Study Group, Cushman W, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. CrossRef ACCORD Study Group, Cushman W, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. CrossRef
12.
Zurück zum Zitat Haller H, Ito S, Izzo JL Jr, ROADMAP Trial Investigators, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17. CrossRefPubMed Haller H, Ito S, Izzo JL Jr, ROADMAP Trial Investigators, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17. CrossRefPubMed
13.
Zurück zum Zitat American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2012;35(Suppl 1):S11–63. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2012;35(Suppl 1):S11–63.
14.
Zurück zum Zitat Schernthaner G, Schernthaner GH. Hypertension and diabetes: need for combination therapy. In: Goldstein BJ, Müller-Wieland D, Herausgeber. Type 2 diabetes. Principle and practice. 3rd Aufl. New York: Informa Healthcare; 2007. Schernthaner G, Schernthaner GH. Hypertension and diabetes: need for combination therapy. In: Goldstein BJ, Müller-Wieland D, Herausgeber. Type 2 diabetes. Principle and practice. 3rd Aufl. New York: Informa Healthcare; 2007.
15.
Zurück zum Zitat Weber M, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, ACCOMPLISH Investigators, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56:77–85. CrossRefPubMed Weber M, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, ACCOMPLISH Investigators, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56:77–85. CrossRefPubMed
16.
Zurück zum Zitat KDIGO. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:405–14. CrossRef KDIGO. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:405–14. CrossRef
17.
Zurück zum Zitat Mann JF, Schmieder RE, McQueen M, ONTARGET investigators, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53. CrossRefPubMed Mann JF, Schmieder RE, McQueen M, ONTARGET investigators, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53. CrossRefPubMed
18.
Zurück zum Zitat Redon J, Mancia G, Sleight P, ONTARGET Investigators, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83. CrossRefPubMed Redon J, Mancia G, Sleight P, ONTARGET Investigators, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83. CrossRefPubMed
19.
Zurück zum Zitat Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7:76–85. CrossRefPubMed Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7:76–85. CrossRefPubMed
20.
Zurück zum Zitat Afghahi H, Svensson MK, Pirouzifard M, et al. Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. Diabetologia. 2015;58:1203–11. CrossRefPubMed Afghahi H, Svensson MK, Pirouzifard M, et al. Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. Diabetologia. 2015;58:1203–11. CrossRefPubMed
21.
Zurück zum Zitat Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56. CrossRefPubMed Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56. CrossRefPubMed
22.
Zurück zum Zitat Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8. CrossRefPubMedPubMedCentral Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W; VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34:34–8. CrossRefPubMedPubMedCentral Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W; VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34:34–8. CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Dormandy JA, Betteridge DJ, Schernthaner G, et al. Impact of peripheral arterial disease in patients with diabetes. Results from PROactive (PROactive 11). Atherosclerosis. 2009;202:272–81. CrossRefPubMed Dormandy JA, Betteridge DJ, Schernthaner G, et al. Impact of peripheral arterial disease in patients with diabetes. Results from PROactive (PROactive 11). Atherosclerosis. 2009;202:272–81. CrossRefPubMed
25.
Zurück zum Zitat Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88. CrossRefPubMed Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88. CrossRefPubMed
26.
Zurück zum Zitat Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the International VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48–53. CrossRefPubMedPubMedCentral Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the International VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48–53. CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:66–70. CrossRefPubMed Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:66–70. CrossRefPubMed
28.
Zurück zum Zitat Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analysis of randomized trials. Circulation. 2011;123:279–10. CrossRef Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analysis of randomized trials. Circulation. 2011;123:279–10. CrossRef
29.
Zurück zum Zitat Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens. 2011;29:1253–69. CrossRefPubMed Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens. 2011;29:1253–69. CrossRefPubMed
30.
Zurück zum Zitat Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26. CrossRef Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26. CrossRef
31.
Zurück zum Zitat James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. CrossRefPubMed James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. CrossRefPubMed
32.
Zurück zum Zitat Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878–85. CrossRefPubMed Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878–85. CrossRefPubMed
33.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52. CrossRefPubMed Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52. CrossRefPubMed
34.
Zurück zum Zitat Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15. CrossRefPubMed Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15. CrossRefPubMed
Metadaten
Titel
Antihypertensive Therapie bei Diabetes mellitus
Leitlinie der österreichischen Diabetesgesellschaft 2016
verfasst von
Guntram Schernthaner
Heinz Drexel
Alexander Rosenkranz
Gerit-Holger Schernthaner
Bruno Watschinger
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0924-2

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Adipositas und Typ 2 Diabetes